TabsDetailsBasic DetailsDate Posted: Tuesday, December 22, 2020Status: CompleteMedical Product: trimethoprim-sulfamethoxazoleHealth Outcome(s): acute respiratory failureDescription: In this report we examined counts of individuals using trimethoprim-sulfamethoxazole (TMP-SMX) and rates of acute respiratory failure (ARF) during treatment. We assessed indications for TMP-SMX dispensing as well as concurrent diagnoses at the time of ARF diagnoses. We repeated the analyses for four other antibiotics of interest.The study period included data from January 1, 2000 to December 31, 2019. We distributed this request to 14 Data Partners on May 15, 2020. Read More Deliverables (1)Sentinel Modular Program Report: Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive AnalysisAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2000 - December 31, 2019Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Individuals aged 6 months-64 yearsData Sources: Sentinel Distributed Database (SDD)